ijms-logo

Journal Browser

Journal Browser

Special Issue "EVs in Cross-Talk between Cancer and Immune Cells"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 31 July 2020.

Special Issue Editor

Prof. Dr. Jarek Baran
Website
Guest Editor
Department of Clinical Immunology, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland
Interests: extracellular vesicles; innate immunity; immunotherapy of cancer; inflammation; tumor immunology

Special Issue Information

Dear Colleagues,

Extracellular vesicles (EVs), their heterogeneity and role in modulation of anticancer immune response or cancer development are a rapidly growing field of research. These highly specific sentinels can transport diverse material (cargo), which may be incorporated both by cells in a local tumor microenvironment and in distant organs and tissues, affecting their functions. As EVs are now being considered a form of communication between cells, it is only fitting to discuss them in the aspect of cellular cross-talk, both in a paracrine and autocrine manner, especially in the context of tumor development. This open-access Special Issue will bring together original research and review articles on these interactions mediated by EVs, with emphasis on cross-talk between cancer and immune cells. 

Topics of this Special Issue include but are not limited to:

  • Identification and new aspects of interactions of cancer and immune cells mediated by EVs of tumor and nontumor origin;
  • Analysis of receptors involved in a cross-talk between cancer and immune cells mediated by EVs;
  • Modification of immune cell functions and activation status by tumor-derived EVs, based on their specific cargo;
  • Tumor promotion and development supported by EVs of immune-cell origin;
  • Techniques for the analysis of specific interactions between cancer and immune cells mediated by EVs.

Prof. Dr. Jarek Baran
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Extracellular vesicles
  • Exosomes
  • Cancer screening and cancer biomarkers
  • Cellular communications
  • microRNA
  • Cancer invasion
  • Metastatic niche
  • Immunomodulation

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle
The Potential of CD16 on Plasma-Derived Exosomes as a Liquid Biomarker in Head and Neck Cancer
Int. J. Mol. Sci. 2020, 21(11), 3739; https://doi.org/10.3390/ijms21113739 - 26 May 2020
Cited by 1
Abstract
Head and neck squamous cell carcinomas (HNSCC) are highly immune suppressive and aggressive malignancies. As part of the tumor microenvironment, exosomes contribute to this immune suppression. The Fc receptor CD16 is widely expressed on monocytes, neutrophils, and natural killer (NK) cells and is [...] Read more.
Head and neck squamous cell carcinomas (HNSCC) are highly immune suppressive and aggressive malignancies. As part of the tumor microenvironment, exosomes contribute to this immune suppression. The Fc receptor CD16 is widely expressed on monocytes, neutrophils, and natural killer (NK) cells and is involved in antibody-dependent cell-mediated cytotoxicity (ADCC). Here, surface levels of CD16 on total exosomes and tumor-derived exosomes (TEX) from plasma of HNSCC patients were analyzed regarding their potential as liquid biomarkers for disease stage. Exosomes were isolated from plasma using mini size exclusion chromatography. TEX were enriched by immune affinity capture with CD44v3 antibodies. On-bead flow cytometry was used to measure CD16 levels on total exosomes and TEX. The results were correlated with clinicopathological parameters. Total exosomes from HNSCC patients had significantly higher CD16 levels compared to TEX. Further, CD16 surface levels of total exosomes, but not TEX, correlated with clinicopathological parameters. Patients with advanced tumor stages T3/4 and Union for International Cancer Control (UICC) stages III/IV had significantly higher CD16 levels on total exosomes compared to patients with early tumor stages T1/2 and UICC stages I/II, respectively. Overall, CD16 positive exosomes have the potential as liquid biomarkers for HNSCC tumor stage and aggressiveness. Full article
(This article belongs to the Special Issue EVs in Cross-Talk between Cancer and Immune Cells)
Show Figures

Figure 1

Open AccessArticle
Mass Spectrometry-Based Proteomic Characterization of Cutaneous Melanoma Ectosomes Reveals the Presence of Cancer-Related Molecules
Int. J. Mol. Sci. 2020, 21(8), 2934; https://doi.org/10.3390/ijms21082934 - 22 Apr 2020
Abstract
Cutaneous melanoma (CM) is an aggressive type of skin cancer for which effective biomarkers are still needed. Recently, the protein content of extracellular vesicles (ectosomes and exosomes) became increasingly investigated in terms of its functional role in CM and as a source of [...] Read more.
Cutaneous melanoma (CM) is an aggressive type of skin cancer for which effective biomarkers are still needed. Recently, the protein content of extracellular vesicles (ectosomes and exosomes) became increasingly investigated in terms of its functional role in CM and as a source of novel biomarkers; however, the data concerning the proteome of CM-derived ectosomes is very limited. We used the shotgun nanoLC–MS/MS approach to the profile protein content of ectosomes from primary (WM115, WM793) and metastatic (WM266-4, WM1205Lu) CM cell lines. Additionally, the effect exerted by CM ectosomes on recipient cells was assessed in terms of cell proliferation (Alamar Blue assay) and migratory properties (wound healing assay). All cell lines secreted heterogeneous populations of ectosomes enriched in the common set of proteins. A total of 1507 unique proteins were identified, with many of them involved in cancer cell proliferation, migration, escape from apoptosis, epithelial–mesenchymal transition and angiogenesis. Isolated ectosomes increased proliferation and motility of recipient cells, likely due to the ectosomal transfer of different cancer-promoting molecules. Taken together, these results confirm the significant role of ectosomes in several biological processes leading to CM development and progression, and might be used as a starting point for further studies exploring their diagnostic and prognostic potential. Full article
(This article belongs to the Special Issue EVs in Cross-Talk between Cancer and Immune Cells)
Show Figures

Figure 1

Review

Jump to: Research

Open AccessReview
Perspectives in Manipulating EVs for Therapeutic Applications: Focus on Cancer Treatment
Int. J. Mol. Sci. 2020, 21(13), 4623; https://doi.org/10.3390/ijms21134623 - 29 Jun 2020
Abstract
Extracellular vesicles (EVs) receive special attention from oncologists due to their assumed usefulness as prognostic markers, vaccines to induce anti-cancer immune response, and physiological delivery tools. The latter application, which supports the reduction of side effects of treatment, is still fraught with many [...] Read more.
Extracellular vesicles (EVs) receive special attention from oncologists due to their assumed usefulness as prognostic markers, vaccines to induce anti-cancer immune response, and physiological delivery tools. The latter application, which supports the reduction of side effects of treatment, is still fraught with many challenges, including established methods for loading EVs with selected cargo and directing them towards target cells. EVs could be loaded with selected cargo either in vitro using several physicochemical techniques, or in vivo by modification of parental cell, which may have an advantage over in vitro procedures, since some of them significantly influence EVs’ properties. Otherwise, our research findings suggest that EVs could be passively supplemented with micro RNAs (miRNAs) or miRNA antagonists to induce expected biological effect. Furthermore, our observations imply that antigen-specific antibody light chains could coat the surface of EVs to increase the specificity of cell targeting. Finally, the route of EVs’ administration also determines their bioavailability and eventually induced therapeutic effect. Besides, EV membrane lipids may possibly possess immune adjuvant activity. The review summarizes the current knowledge on the possibilities to manipulate EVs to use them as a delivery tool, with the special emphasis on anti-cancer therapy. Full article
(This article belongs to the Special Issue EVs in Cross-Talk between Cancer and Immune Cells)
Show Figures

Graphical abstract

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Myeloid cell modulation by tumor-derived EVs
Authors: Viktor Umansky; et al.

Title: Tumor-derived exosomes and their role in cancer progression and immune therapies of cancer
Authors: Theresa L. Whiteside; et al.

Back to TopTop